Delphine Sapaly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Delphine Sapaly has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Charbonnier
Universite Paris Cite
2 shared publications - Laure Weill
Universite Paris Cite
2 shared publications Rasha Slika
2 shared publications- Agnès Conjard-Duplany
Laboratoire Physiopathologie et Génétique du Neurone et du Muscle (PGNM), Institut NeuroMyoGène, Université Claude Bernard Lyon 1, INSERM U1315, CNRS UMR 5261, Lyon, France
1 shared publication - Alexis Osseni
Institut NeuroMyoGène, Physiopathologie et Génétique du Neurone et du Muscle, UMR CNRS 5261 – INSERM U1315, Université Claude Bernard Lyon 1, Lyon, France
1 shared publication Anthony Behin
1 shared publication
Latest Publications
- Open Access
Progressive muscle metabolic reprogramming in asymptomatic ALS gene mutation carriers
Amyotrophic lateral sclerosis (ALS) is a rapidly fatal neurodegenerative disorder characterized by motor neuron loss leading to extensive paralysis. There is emerging evidence that the disease involves a prolonged presymptomatic period during which motor function is preserved. Understanding the molecular mechanisms involved is key as the presymptomatic phase represents a critical window of opportunity for early intervention. Using RNA sequencing, we investigated changes in gene expression patterns in the skeletal muscle of ten asymptomatic carriers of ALS mutations (8 C9ORF72 expansion carriers and 2 SOD1 mutation carriers). We found that specific modifications of gene expression profiles are present in skeletal muscle before asymptomatic ALS gene carriers exhibit biomarker changes predictive of phenoconversion. We identified insulin signaling, AMPK signaling, and thermogenesis pathways, together with the TCA cycle as the main contributors to the dysregulated muscle transcriptome. Our data suggest that this metabolic reprogramming of skeletal muscle develops progressively during the transition to phenoconversion, characterized by a gradual increase in the expression of SREBF1 which encodes SREPB1, the key transcriptional regulator of lipid synthesis, in parallel with the progressive activation of AMPK and insulin signaling pathways. Our findings are consistent with a progressive enhancement in fatty acid metabolism and oxidative capacity in skeletal muscle, followed by a decline in oxidative phosphorylation efficiency as phenoconversion approaches. Evidence of muscle metabolic reprogramming in ALS long before motor onset identifies the dysregulation of muscle energy homeostasis as a critical early event in ALS pathogenesis.
Open AccessProgressive muscle metabolic reprogramming in asymptomatic ALS gene mutation carriers
Amyotrophic lateral sclerosis (ALS) is a rapidly fatal neurodegenerative disorder characterized by motor neuron loss leading to extensive paralysis. There is emerging evidence that the disease involves a prolonged presymptomatic period during which motor function is preserved. Understanding the molecular mechanisms involved is key as the presymptomatic phase represents a critical window of opportunity for early intervention. Using RNA sequencing, we investigated changes in gene expression patterns in the skeletal muscle of ten asymptomatic carriers of ALS mutations (8 C9ORF72 expansion carriers and 2 SOD1 mutation carriers). We found that specific modifications of gene expression profiles are present in skeletal muscle before asymptomatic ALS gene carriers exhibit biomarker changes predictive of phenoconversion. We identified insulin signaling, AMPK signaling, and thermogenesis pathways, together with the TCA cycle as the main contributors to the dysregulated muscle transcriptome. Our data suggest that this metabolic reprogramming of skeletal muscle develops progressively during the transition to phenoconversion, characterized by a gradual increase in the expression of SREBF1 which encodes SREPB1, the key transcriptional regulator of lipid synthesis, in parallel with the progressive activation of AMPK and insulin signaling pathways. Our findings are consistent with a progressive enhancement in fatty acid metabolism and oxidative capacity in skeletal muscle, followed by a decline in oxidative phosphorylation efficiency as phenoconversion approaches. Evidence of muscle metabolic reprogramming in ALS long before motor onset identifies the dysregulation of muscle energy homeostasis as a critical early event in ALS pathogenesis.
- Open Access
Combining SMN2 splicing modifiers with HDAC6 inhibition greatly improves muscle function and survival in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare, progressive and severe neuromuscular disease. It is mostly caused by mutations in the SMN gene, which lead to the death of spinal cord motor neurons. In the absence of treatment, more than half of affected children die before the age of two. Recently, groundbreaking gene therapies were developed, allowing children to survive. However, a new clinical presentation of the disease has emerged in treated patients, characterized by ongoing functional deficits and a disability mainly due to persistent muscle atrophy. Over the last years, treatments of various animal models of neuromuscular disorders have shown the ability of inhibitors of the non-conventional histone deacetylase 6 (HDAC6) to reduce inflammation, fibrosis and muscle atrophy, and to ameliorate acetylcholine receptor distribution at the neuromuscular junction, microtubule network and mitochondrial transport in axons, indicating potential interest for the treatment of neuromuscular disorders. The present study was designed to properly characterize the effect of HDAC6 inhibition on muscle cells proliferation and differentiation and to evaluate in vivo if HDAC6 inhibition combined with the new standard of care treatments of SMA could ameliorate skeletal muscle and general status of a SMA mouse model. Here, we report that HDAC6 and tubulin acetylation controls myotube formation and maturation in vitro. In particular, HDAC6 inhibition increases the size of SMA patients-derived muscle primary myotubes. In vivo, when combined with ASOs inducing exon 7 inclusion in SMN2 RNA in motoneurons, HDAC6 systemic inhibition strongly improved muscle strength, mass, function, and longevity of the SmnΔ7/Δ7; hSMN2+/− mouse model of SMA. These findings provide evidence that in muscle cells, HDAC6 is the only tubulin deacetylase and that selective inhibition of HDAC6 improves myogenic progression and that HDAC6 inhibitors are good candidates to ameliorate persisting symptoms of SMA patients treated with the new standard of care.
Open AccessCombining SMN2 splicing modifiers with HDAC6 inhibition greatly improves muscle function and survival in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare, progressive and severe neuromuscular disease. It is mostly caused by mutations in the SMN gene, which lead to the death of spinal cord motor neurons. In the absence of treatment, more than half of affected children die before the age of two. Recently, groundbreaking gene therapies were developed, allowing children to survive. However, a new clinical presentation of the disease has emerged in treated patients, characterized by ongoing functional deficits and a disability mainly due to persistent muscle atrophy. Over the last years, treatments of various animal models of neuromuscular disorders have shown the ability of inhibitors of the non-conventional histone deacetylase 6 (HDAC6) to reduce inflammation, fibrosis and muscle atrophy, and to ameliorate acetylcholine receptor distribution at the neuromuscular junction, microtubule network and mitochondrial transport in axons, indicating potential interest for the treatment of neuromuscular disorders. The present study was designed to properly characterize the effect of HDAC6 inhibition on muscle cells proliferation and differentiation and to evaluate in vivo if HDAC6 inhibition combined with the new standard of care treatments of SMA could ameliorate skeletal muscle and general status of a SMA mouse model. Here, we report that HDAC6 and tubulin acetylation controls myotube formation and maturation in vitro. In particular, HDAC6 inhibition increases the size of SMA patients-derived muscle primary myotubes. In vivo, when combined with ASOs inducing exon 7 inclusion in SMN2 RNA in motoneurons, HDAC6 systemic inhibition strongly improved muscle strength, mass, function, and longevity of the SmnΔ7/Δ7; hSMN2+/− mouse model of SMA. These findings provide evidence that in muscle cells, HDAC6 is the only tubulin deacetylase and that selective inhibition of HDAC6 improves myogenic progression and that HDAC6 inhibitors are good candidates to ameliorate persisting symptoms of SMA patients treated with the new standard of care.
- Open Access
- 18 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10039
Understanding the Role of the SMN Complex Component GEMIN5 and Its Functional Relationship with Demethylase KDM6B in the Flunarizine-Mediated Neuroprotection of Motor Neuron Disease Spinal Muscular Atrophy
Dysregulated RNA metabolism caused by SMN deficiency leads to motor neuron disease spinal muscular atrophy (SMA). Current therapies improve patient outcomes but achieve no definite cure, prompting renewed efforts to better understand disease mechanisms. The calcium channel blocker flunarizine improves motor function in Smn-deficient mice and can help uncover neuroprotective pathways. Murine motor neuron-like NSC34 cells were used to study the molecular cell-autonomous mechanism. Following RNA and protein extraction, RT-qPCR and immunodetection experiments were performed. The relationship between flunarizine mRNA targets and RNA-binding protein GEMIN5 was explored by RNA-immunoprecipitation. Flunarizine increases demethylase Kdm6b transcripts across cell cultures and mouse models. It causes, in NSC34 cells, a temporal expression of GEMIN5 and KDM6B. GEMIN5 binds to flunarizine-modulated mRNAs, including Kdm6b transcripts. Gemin5 depletion reduces Kdm6b mRNA and protein levels and hampers responses to flunarizine, including neurite extension in NSC34 cells. Moreover, flunarizine increases the axonal extension of motor neurons derived from SMA patient-induced pluripotent stem cells. Finally, immunofluorescence studies of spinal cord motor neurons in Smn-deficient mice reveal that flunarizine modulates the expression of KDM6B and its target, the motor neuron-specific transcription factor HB9, driving motor neuron maturation. Our study reveals GEMIN5 regulates Kdm6b expression with implications for motor neuron diseases and therapy.
- 18 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10039
Open AccessUnderstanding the Role of the SMN Complex Component GEMIN5 and Its Functional Relationship with Demethylase KDM6B in the Flunarizine-Mediated Neuroprotection of Motor Neuron Disease Spinal Muscular Atrophy
Dysregulated RNA metabolism caused by SMN deficiency leads to motor neuron disease spinal muscular atrophy (SMA). Current therapies improve patient outcomes but achieve no definite cure, prompting renewed efforts to better understand disease mechanisms. The calcium channel blocker flunarizine improves motor function in Smn-deficient mice and can help uncover neuroprotective pathways. Murine motor neuron-like NSC34 cells were used to study the molecular cell-autonomous mechanism. Following RNA and protein extraction, RT-qPCR and immunodetection experiments were performed. The relationship between flunarizine mRNA targets and RNA-binding protein GEMIN5 was explored by RNA-immunoprecipitation. Flunarizine increases demethylase Kdm6b transcripts across cell cultures and mouse models. It causes, in NSC34 cells, a temporal expression of GEMIN5 and KDM6B. GEMIN5 binds to flunarizine-modulated mRNAs, including Kdm6b transcripts. Gemin5 depletion reduces Kdm6b mRNA and protein levels and hampers responses to flunarizine, including neurite extension in NSC34 cells. Moreover, flunarizine increases the axonal extension of motor neurons derived from SMA patient-induced pluripotent stem cells. Finally, immunofluorescence studies of spinal cord motor neurons in Smn-deficient mice reveal that flunarizine modulates the expression of KDM6B and its target, the motor neuron-specific transcription factor HB9, driving motor neuron maturation. Our study reveals GEMIN5 regulates Kdm6b expression with implications for motor neuron diseases and therapy.